Literature DB >> 34055345

Postoperative solitary liver metastasis from esophageal squamous cell carcinoma achieving a clinical complete response to chemotherapy with cisplatin and 5-fluorouracil followed by stereotactic body radiotherapy: A case report.

Shuichi Fukuda1, Kaoru Okajima2, Kaoru Okada1, Kohei Fukuda2, Tomoko Wakasa3, Tomoyuki Tsujimoto1, Atsushi Gakuhara1, Hideo Tomihara1, Katsuya Ohta1, Kotaro Kitani1, Kazuhiko Hashimoto1, Hajime Ishikawa1, Jin-Ichi Hida1, Masao Yukawa1, Yoshio Ohta3, Masatoshi Inoue1.   

Abstract

Treatment strategies for distant organ metastasis have changed markedly since the concept of oligometastasis was introduced. The perception that distant organ metastasis is a systemic disease and not eligible for local therapy is now a thing of the past. Therefore, the present report details a case of postoperative solitary liver metastasis from esophageal squamous cell carcinoma (ESCC), which achieved a clinical complete response to chemotherapy with cisplatin and 5-fluorouracil (5-FU) followed by stereotactic body radiotherapy (SBRT). A 76-year-old male patient underwent esophagectomy for lower thoracic ESCC. At 7 months after surgery, abdominal CT revealed a solitary hypovascular mass, 28 mm in size, in segment 7 of the liver. After three courses of chemotherapy with cisplatin and 5-FU, abdominal CT revealed that the liver mass had shrunk to 7 mm in size. SBRT was then administered with a 6 MV X-ray beam generated by a linear accelerator. A total dose of 50 Gy was given in 5 fractions of 10 Gy to the liver mass. At 1 month after SBRT, abdominal CT revealed that the liver mass had disappeared. The patient received no further adjuvant chemotherapy and had no recurrence at 18 months after diagnosis of liver metastasis and 13 months after SBRT. Copyright: © Fukuda et al.

Entities:  

Keywords:  esophageal cancer; liver metastases; oligometastasis; oligorecurrence; stereotactic ablative radiotherapy

Year:  2021        PMID: 34055345      PMCID: PMC8138851          DOI: 10.3892/mco.2021.2292

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  20 in total

1.  Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.

Authors:  H Bleiberg; T Conroy; B Paillot; A J Lacave; G Blijham; J H Jacob; L Bedenne; M Namer; P De Besi; F Gay; L Collette; T Sahmoud
Journal:  Eur J Cancer       Date:  1997-07       Impact factor: 9.162

2.  Predictors of Survival After Treatment of Oligometastases After Esophagectomy.

Authors:  Galal Ghaly; Sebron Harrison; Mohamed K Kamel; Mohamed Rahouma; Abu Nasar; Jeffrey L Port; Brendon M Stiles; Nasser K Altorki
Journal:  Ann Thorac Surg       Date:  2017-12-21       Impact factor: 4.330

3.  Oligometastases.

Authors:  S Hellman; R R Weichselbaum
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

4.  Radiofrequency ablation for pulmonary metastases from esophageal squamous cell carcinoma.

Authors:  Y Baba; M Watanabe; K Kawanaka; S Iwagami; T Ishimoto; M Iwatsuki; N Yoshida; Y Yamashita; H Baba
Journal:  Dis Esophagus       Date:  2013-02-05       Impact factor: 3.429

Review 5.  Stereotactic body radiation therapy for liver metastases.

Authors:  Omar Dawood; Anand Mahadevan; Karyn A Goodman
Journal:  Eur J Cancer       Date:  2009-09-19       Impact factor: 9.162

Review 6.  Oesophageal carcinoma.

Authors:  Arjun Pennathur; Michael K Gibson; Blair A Jobe; James D Luketich
Journal:  Lancet       Date:  2013-02-02       Impact factor: 79.321

7.  Clinicopathologic Characteristics of Oligometastases from Esophageal Cancer and Long-Term Outcomes of Resection.

Authors:  Yu Ohkura; Junichi Shindoh; Masaki Ueno; Toshiro Iizuka; Harushi Udagawa
Journal:  Ann Surg Oncol       Date:  2020-01-02       Impact factor: 5.344

8.  Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.

Authors:  Eric J Lehrer; Raj Singh; Ming Wang; Vernon M Chinchilli; Daniel M Trifiletti; Piet Ost; Shankar Siva; Mao-Bin Meng; Leila Tchelebi; Nicholas G Zaorsky
Journal:  JAMA Oncol       Date:  2021-01-01       Impact factor: 31.777

9.  Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2.

Authors:  Yuko Kitagawa; Takashi Uno; Tsuneo Oyama; Ken Kato; Hiroyuki Kato; Hirofumi Kawakubo; Osamu Kawamura; Motoyasu Kusano; Hiroyuki Kuwano; Hiroya Takeuchi; Yasushi Toh; Yuichiro Doki; Yoshio Naomoto; Kenji Nemoto; Eisuke Booka; Hisahiro Matsubara; Tatsuya Miyazaki; Manabu Muto; Akio Yanagisawa; Masahiro Yoshida
Journal:  Esophagus       Date:  2018-08-31       Impact factor: 3.671

10.  Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review.

Authors:  Sara Jamel; Karina Tukanova; Sheraz Markar
Journal:  World J Gastrointest Oncol       Date:  2019-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.